Evidence map›Paper›PMID 33491475›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Gender Differences in Concerns About Participating in Cancer Research During the COVID-19 Pandemic.

Louis Fox, Harriet Wylie, Fee Cahill, Anna Haire, Saran Green, Joyce Kibaru, Catherine Hartley, Richard Sullivan, Mieke Van Hemelrijck

Abstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Louis FoxTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.ORCID https://orcid.org/0000-0002-8280-1797
Harriet WylieTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.
Fee CahillTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.
Anna HaireTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.
Saran GreenTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.
Joyce KibaruTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.
Catherine HartleyEcancer, Bristol, United Kingdom.
Richard SullivanInstitute of Cancer Policy, King's College London, United Kingdom.
Mieke Van HemelrijckTranslational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.ORCID https://orcid.org/0000-0002-7317-0858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe ongoing SARS-CoV-2 pandemic is having major effects on cancer research, including major reductions in participant accrual to cancer clinical trials. Existing research has indicated that these steep drops in accrual rates to cancer clinical trials may be disproportionately affecting women. We sought to determine if there were gender differences in a dataset collected to examine participants' concerns about taking part in cancer research during the pandemic.

methodsBetween 5-19 June 2020, we distributed a fully anonymized survey via social media. We contacted 85 UK cancer patient organizations/charities and asked them to share our questionnaire on their platforms, of which 26 obliged. Patients aged 18 with a cancer diagnosis were eligible to participate and asked about their clinical and demographic characteristics, concerns about research participation given the COVID-19 pandemic, anxiety levels measured using the Generalized Anxiety Disorder-7 (GAD-7) scale, amongst other questions. Anxiety levels and concerns about participating were compared between men and women using univariate and multivariate analyses.

results93 individuals, comprising n = 37 women and n = 56 men of various cancer types, provided survey responses. Independent t-tests showed that women reported higher anxiety scores, and concerns about participating in cancer research during COVID-19, than men. Linear regression analyses showed that anxiety scores predicted concerns about research participation in women but not men (p

conclusionsCancer patients have concerns about participating in research during the COVID-19 pandemic that range from mild to serious. Furthermore, the relationship between general anxiety and concerns about research participation may be both more relevant and more pronounced in women than in men. Future work should examine the reasons why women are less likely to enrol in cancer trials during the COVID-19 pandemic.

Indexed as

AdultAgedAged, 80 and overAnxietyCOVID-19FemaleHumansMaleMiddle AgedNeoplasmsPatient ParticipationSARS-CoV-2Sex FactorsSurveys and QuestionnairesanxietycoronavirusengagementgenderoncologySARS-CoV-2

Identifiers

PMID33491475
PMCPMC8482716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.